1	Association between frailty assessed by the Clinical Frailty Scale 2.0 and outcomes of acute stroke in
2	older patients
3	
4	Paola Forti, MD, PhD, Department of Medical and Surgical Sciences (DIMEC) University of Bologna,
5	Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna
6	Marianna Ciani, MD, Department of Medical and Surgical Sciences (DIMEC) University of Bologna,
7	Bologna
8	Fabiola Maioli, MD, Geriatric Unit, Department of Integrated Care, Ospedale Maggiore, Bologna
9	
10 11	Heading: Frailty and outcomes of acute stroke
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	

- 25
- 26 27
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

2

28 Abstract

Background: Frailty is a geriatric syndrome characterized by an increased vulnerability to stressors and increased risk of adverse clinical outcomes. While older patients with acute stroke are routinely screened for prestroke disability using the modified Rankin Scale (mRS), because of its known association with stroke outcomes, prestroke frailty is still rarely assessed. The Clinical Frailty Scale (CFS) is a popoular tool for retrospective frailty assessment in the acute setting. The study hypothesis was that prestroke frailty measured with CFS was associated with stroke outcome of older patients independent of prestroke disability assessed with mRS.

36 Methods: We recruited 4086 individuals aged \geq 65 years consecutively admitted with acute stroke to an

37 Italian hospital. Prestroke disability (mRS \geq 3) was assessed at admission. Prestroke CFS was retrospectively

assessed using information from the medical records. Logistic models determined the association of CFS

39 with poor functional outcome, prolonged discharge, unfavorable discharge setting, and poor rehabilitation

40 potential. Cox models determined the association of CFS with 30-day and 1-month mortality. All models

41 were adjusted for prestroke disability and other major confounders.

42 **Results:** Participants were median age 81 years (25th-75th percentile, 75-87 years), 55.0% female, 82.6%

43 with ischemic stroke, and 26.3% with prestroke disability. Overall prevalence of prestroke frailty (CFS \geq 4)

44 was 41.6%. Multivariable-adjusted logistic models showed that CFS was associated with increasing risk of

45 all outcomes except prologed discharge. In severe frailty (CFS 7-8), OR (95%CI) was 3.44 (2.33-5.07) for

46 poor functional outcome, 0.53 (0.38-0.75) for prolonged discharge, 1.89 (0.36-263) for unfavourable

discharge, and 6.24 (3.80-10.26) for poor rehabilitation potential (reference CFS 1-3). In multivariable

48 adjusted- Cox models, CFS was unrelated to 30-day mortality but HR (95%CI) of 1-year mortality was

49 significant for both CFS 4-6 (1.70, 1.36-2.11) and CFS 7-8 (1.69, 1.25-2.30).

50 Conclusions: Prestroke frailty measured with CFS was associated with higher risk of several adverse

51 outcomes even after adjustment for prestroke disability and other major confounders.

52

53 Key Words: frailty, stroke, disability, aged

- 54
- 55

3

56 Introduction

Frailty is a geriatric syndrome characterized by an increased vulnerability to stressors that is caused by a
cumulative decline across multiple physiological systems.¹ Frailty can explain the heterogeneity in overall
health of older persons, it is associated with several adverse clinical outcomes, and its assessment can
provide useful prognostic information to guide clinical decision-making and therapeutic interventions in
older patients.² Although frail older persons are often disabled and with multiple chronic conditions, frailty is
considered a distict entity from both disability and comorbidity.¹

63 Stroke is a prototypical stressor event but frailty is rarely mentioned in best practice guidelines on stroke and not yet routinely measured in stroke patients.^{3,4} In current clinical practice and research, prestroke disability 64 retrospectively assessed with the modified Rankin Scale (mRS)⁵ is acknowledged as a robust prognostic 65 66 predictor of stroke outcomes^{6,7} and, therefore, a commonly used criterion to assist in determining eligibility for hyperacute reperfusion therapies.^{8,9} The mRS is easy to use in a time-pressured setting but was actually 67 68 designed for assessment of post-stroke functional outcome, with an emphasis on mobility over cognitive disability and comorbidity.^{6,9} Therefore, it may not be a valid measure of pre-stroke global function and 69 70 overall health, in older persons.¹⁰ A variety of frailty tools have been developed that widely differ on types of measurements and clinical feasibility.¹¹ There is still no standard assessment tool for frailty.¹² In clinical 71 practice, the choice of a frailty tool depends on the purpose, setting, time availability, and assessor skills.¹³ 72 The Clinical Frailty Scale (CFS)¹⁴ is one of the most popular tools for retrospective frailty assessment in the 73 acute^{15,16} and hyperacute care setting.¹⁷ Advantages of CFS include: the tool is based on clinical judgement 74 and does not require performance tests; it focuses on mobility, function, cognition, and comorbidity; it 75 76 involves a nine-point pictorial scale paired with corresponding text describing classifications of frailty; and it can be readily used by a health care professional without specialist training.¹⁴ CFS seems a pragmatic and 77 78 easy choice to assess prestroke frailty in older individuals with acute stroke⁴ but available information about this topic is limited.^{18–22} 79

The primary hypothesis of this study is that prestroke frailty assessed with CFS is associated with stroke outcomes of older patients independent of prestroke disability assessed with mRS. A secondary hypothesis tested in this study is that prestroke CFS and mRS have low agreement and different predictive ability for stroke outcomes.

4

Methods 85

86 Study cohort

This is a retrospective observational study based on a single-center cohort of 4094 patients aged ≥ 65 years 87 who, between January 2006 and December 2018, were consecutively admitted to the Emergency Department 88 89 (ED) of the Maggiore Hospital (Bologna, Italy) within 24 hours after onset of acute stroke and subsequently transferred to the local Stroke Unit (SU). All patients had at least one CT-head scan at ED admission. Only 90 91 patients with a final diagnosis of ischemic stroke (IS) and primary intracerebral hemorrhage (ICH) were considered eligible. Patients with transient ischemic attack, subarachnoid hemorrhage, and secondary ICH due 92 to underlying vascular malformations and intracranial tumors were excluded. Stroke severity at admission was 93 assessed using the National Institutes of Health Stroke Scale (NIHSS) score,²³ categorized as <6, 6-15, and 94 >15.²⁴ Patients were treated according to standard guidelines for management of acute stroke.²⁵ In IS patients, 95 96 the decision to perform reperfusion therapies (intravenous thrombolysis using the fibrinolytic agent alteplase 97 or endovascular thrombectomy) was based on clinical judgment.

98

99 Prestroke frailty and disability

100 At the time of ED admission, the stroke consultant on duty retrospectively assessed mRS in the two preceeding 101 weeks (pre-mRS) based on an unstructured direct interview with the patient and, whenever possible, a knowledgeable proxy (relatives and usual caretakers). Prestroke disability was defined as pre-mRS ≥ 3.26 102 103 Concurrent frailty level according to CFS version 2.0^{27} (Figure 1) was retrospectively assessed by two authors (P.F. and M.C.) based on any available information on premorbid mobility, function, cognition, and medical 104 history as documented in the patient chart. Prestroke frailty was defined as $CFS \ge 4$ and further graded as mild-105 to-moderate (CFS 4 to 6) and severe-to-terminal (CFS 7 to 8).²⁷ Patients with CFS 9 were excluded from 106 107 further analyses because this level identifies persons whose life expectancy is shorter than six months but are not otherwise living with frailty, which disrupts the progression of frailty from CFS 1 to 8.²⁸ Similarly to what 108 would happen in real clinical practice, CFS raters were not blind to pre-mRS. Retrospective CFS scoring using 109 information not primarily intended for this goal has been validated with good reliability and accuracy.^{29,30} 110

112 Other prestroke variables

Baseline demographic and clinical data were extracted from the patient charts. Comorbidity was defined using the Charlson Comobidity Index (CCI)³¹, which takes into account the number and severity of 19 pre-defined comorbid conditions. CCI score was categorized as 0, 1, 2-3, and ≥ 4.32

- 116
- 117 Outcomes

118 SU attending physicians re-assessed mRS at discharge (discharge-mRS). Poor functional outcome was

defined as discharge-mRS >1 for patients with pre-stroke mRS <2 and as discharge-mRS greater than pre-

mRS for patients with pre-mRS 2-4; patients with pre-mRS 5 were excluded because they would have a

favourable outcome just surviving.¹⁰ Prolonged discharge was defined as length of SU stay >7 days.³³

122 Discharge destination was defined "favorable" (home or rehabilitation facility) or "unfavourable" (long-term

123 care facility, another acute hospital setting, or in-hospital death).³⁴ In a subgroup analysis, poor rehabilitation

124 potential, defined as discharge to long-term care, was contrasted to discharge to rehabilitation facilities.

125 All-cause mortality at 30-day and 1-year after stroke onset was ascertained from the Italian Regional

126 Mortality Registry. In IS patients treated with reperfusion therapies, percentage improvement in NIHSS after

treatment was calculated as (admission NIHSS score minus discharge NIHSS score)×100/admission NIHSS

score.

129

130 Statistical analysis

Data are reported as count (percentages) for categorical variables or median (25th-75th percentile) for continuous variables. Univariate comparisons between groups were performed using chi-square test or Kruskal-Wallis test as appropriate. Agreement between CFS and pre-mRS was assessed using weighted kappa³⁵. Predictive ability of both scales for the study outcomes was estimated using the Area under the Receiver Operating Characteristic curves (AuROC). Confidence intervals were calculated according to binomial exact formula. DeLong's method was used for AuROC comparison.³⁶

The association of CFS categories with all study outcomes excepting mortality was assessed using Odds Ratios
(OR) and their 95% confidence intervals (95%CI) from logistic models. The association of CFS categories
with mortality was assessed using Hazard Ratios (HR) and their corresponding 95%CI from Cox proportional

6

140 hazard models. A priori chosen confounders for adjusted models included: age, sex, CCI score, stroke subtype, 141 admission NIHSS, and prestroke disability. Effect modification of CFS by model confounders was 142 systematically assessed and interactions were considered significant for p-value < 0.010. In subanalyses of treated IS patients, confounders for adjusted models included age, sex, CCI score and prestroke disability. The 143 association of CFS categories with NIHSS improvement was assessed using linear regression. For the other 144 145 study outcomes, treated IS patients were classified as frail vs non-frail because of insufficient sample size. 146 Analyses were performed with R software version 3.5.3. Significance for P value was set at the 0.050 (two-147 tailed). 148 Standard Protocol Approvals, Registrations, and Patient Consents 149 At SU admission, written informed consent for research use of their medical records was sought from patients 150

151 or their legally authorized representatives according to the Declaration of Helsinki. The Maggiore Hospital

152 Ethics Committee approved the study (approval number CE16092).

153

154 *Data Availability*

155 Data for this study will be made available by request from any qualified investigator.

156

157 Results

158 Clinical and demographic factors

159 After exclusion of eight persons with CFS 9, the final cohort included 4086 patients; 2249 were women

160 (55.0%) and median age was 81 years (25th-75th percentile, 75-87 years). Overall prevalence of prestroke

161 frailty was 41.6% (29.4% for CFS 4-6 and 12.2% for CFS 7-8). Only twelve patients were classified as CFS

162 1 ("very fit"). *Supplemental Figure F1* shows how frailty prevalence increased from 14.7% at age 65-69 to

163 78.7% at age \ge 90 years.

164 Table 1 shows how increasing CFS was associated with age, female sex, living in nursing home before 165 admission, prestroke disability, and comorbidity. IS was the most frequent stroke subtype in all CFS categories 166 and stroke severity increased with increasing fraily. Occurrence of all study outcomes increased across 167 increasing CFS categories excepting prolonged discharge, which was lowest for CFS 7-8. *Supplemental Table*

7

T1 provides information about the number of patients for each outcome by CFS category. *Supplemental Figure F2* provides information about the distribution of pre- and discharge-mRS across CFS categories.

- 170
- 171 Agreement between CFS and pre-mRS

172 Overall prevalence of prestroke disability was 26.3%. Prestroke frailty was identified in 21.3% of those

173 without prestroke disability. Prestroke disability was recorded only in 0.7% of non-frail patients. Figure 2

shows how pre-mRS levels 0 to 2 and CFS levels 1 to 3 tended overlap while there was a noticeable

dispersion of pre-mRS levels across CSF levels above 3, even with some patients classified as totally

independent according to pre-mRS but moderately to severely frail according to CFS. Weighted kappa for

177 CFS and pre-mRS was 0.56, suggestive of only moderate agreement.³⁵

178

179 Predictive ability of CFS and pre-mRS for the study outcomes

180 Comparison of AuROCs (**Table 2**) showed that CFS was statistically superior to pre-mRS for prediction of 181 poor functional outcome, unfavorable discharge, and poor rehabilitation potential while no difference was 182 found for the other study outcomes. However, AuROCs for both scales were below the traditional 0.80 183 threshold for clinical usefulness.³⁷

184

185 *Multivariable-adjusted association of CFS with the study outcomes*

Figure 3 summarizes the results from adjusted logistic (Panel A) and Cox models for the association of CFS

187 with the study outcomes. Likelihood of poor functional outcome, unfavorable discharge, and poor

rehabilitation potential increased with increasing frailty level while likelihood of prolonged discharge was

almost halved for CFS 7-8 compared to CFS 1-3. Results for unfavorable discharge did not change when

excluding 222 patients already living in institution before hospital admission (CFS 4-6: adjusted-OR, 1.46,

191 95% CI 1.17-1.82; CFS 7-8: adjusted-OR 2.66, 95% CI 1.85-3.81). There was no significant association of

- 192 CFS with 30-day mortality but 1-year mortality risk was significantly increased for both CFS 4-6 and 7-8
- 193 compared to CFS 1-3. In all models, both the independent effect of prestroke disability on outcome
- 194 prediction and its interaction with CFS categories were not significant (p-value > 0.200 for all).
- 195 IS patients treated with reperfusion therapies

8

196 There were 3374 patients with IS (82.6%). Cardioembolism was the most frequent etiology (35.2%), 197 followed by cryptogenic (33.4%), small vessel occlusion (19.9%), large artery atherosclerosis (9.9%), 198 multiple causes (1.0%) and other causes (0.6%). Reperfusion therapies were performed in 498 patients 199 (14.8%): 83.5% received intravenous thrombolysis, 4.2% mechanical thrombectomy, and 12.2% both. Only 25.9% of treated patients were frail compared to 44.5% of non-treated patients but adjusted-OR was not 200 significant (1.00, 95%CI 0.74-1.34). Among treated patients, overall prevalence of prestroke disability was 201 202 only 12% but the proportion was much higher in frail (45.7%) compared to non-frail patients (just one case, 203 0.3%). Figure 4 shows the results from adjusted logistic (Panel A) and Cox models (Panel B) for the 204 association of frailty with the study outcomes in treated IS patients. Significant associations were found for 205 poor functional outcome (74% of 127 frail vs 43.6% of 369 non-frail patients) and poor rehabilitation 206 potential (40.9% of 66 frail vs 8.6% of 139 non-frail patients) but not for prolonged (42.3% of 97 frail vs 207 34.9 of 278 non-frail patients) and unfavorable discharge (45.4% of 129 frail vs 27.9% of 369 non-frail patients). Because of the small number of cases (n=77), only the association of frailty with overall mortality 208 209 during a 1-year follow-up could be estimated. Mortality rate was higher in frail compared to non-frail 210 patients (36.1% vs 8.4%) and the corresponding adjusted-HR was 2.36, 95%CI 1.24-4.50. 211 Among treated patients, stroke severity was higher in frail than non-frail persons (31.0% vs 19% with admission NIHSS >15, p-value = 0.012). However, median percentage improvement in NIHSS after 212 213 reperfusion therapy had a U-shaped relationship with CFS score (Supplemental Figure F3). The adjusted 214 linear model confirmed that median NIHSS improvement for CFS 1-3 (71%, 35%-100%) was higher 215 compared to CFS 4-6 (59%, 12%-79%, p-value = 0.003) but did not differ compared to CFS 7-8 (78%, 49-216 84%, p-value = 0.708). 217 In all of the above reported models, both the independent effect of prestroke disability on outcome prediction

and its interaction with frailty were not significant (p-value > 0.200 for all).

219

220 Discussion

This cohort study of older patients with acute stroke showed that prestroke frailty retrospectively assessed
 using CFS version 2.0 was highly prevalent and may convey additional prognostic information for several
 stroke outcomes with respect to prestroke disability assessed using mRS.

9

224 Previous studies of frailty occurrence in older stroke patients produced inconsistent results, mainly because 225 of the great heterogeneity in the operational definition of frailty (estimates ranging from 2% to 68%).^{3,38} 226 Most of these studies are not comparable with ours because they used variations of the physical frailty phenotype, which is based on motor and activity measures, or frailty cumulative indexes, which variably 227 incorporate measures of function, cognition, comorbidities, and social factors.² Two studies of IS patients 228 229 using CFS reported frailty prevalence estimates ranging between 38%²⁰ and 54%,¹⁸ which agree with our 230 findings. However, comparability is limited because these studies used an older version of CFS, in which level 5 is the first including the term frail in its description¹⁴ and, accordingly, frailty was defined as CFS \geq 5. 231 The association of CFS with age, female gender, and comorbidity found in our cohort is not surprising 232 because it reflects known general features of frailty.² In this older cohort, we also found no difference in 233 234 frailty prevalence by stroke type. A metanalysis of 24 studies reported that frailty was more prevalent in IS than ICH,³⁸ but this result may derive from the inclusion of studies involving patients aged less that 65 years, 235 236 with data for ICH mostly coming from younger cohorts.

237 Our investigation provided evidence of unfavourable associations between increasing CFS and all of the 238 study outcomes excepting prolonged discharge. The associations of CFS with outcomes related to discharge 239 setting, functional status at SU discharge, and mortality can have several explanations: acute stroke and frailty can exacerbate each other and trigger a self-propagating cycle; frailty can also influence several 240 241 physical and non-physical aspects of stroke recovery, including acute complications (in particular delirium 242 and infections), malnutrition, post-stroke cognitive impairment, and effectiveness of rehabilitation and psychosocial interventions.^{4,39} Our frailest patients also had a shorter SU stay, but our study design does not 243 244 allow to understand whether this happened because frailest patients were correctly spared futile diagnostic 245 and therapeutic procedures or actually received suboptimal care.

Existing evidence that frailty can provide prognostic information additional to major stroke predictors such
as age, stroke severity, and pre-mRS is still weak. A metanalysis of 14 stroke studies³ reported associations
of frailty with longer hospital stay, poor functional outcome, discharge destination, and long-term mortality.
However, the authors stressed the low number of eligible studies for the individual outcomes and the
heterogeneity of the tools employed for frailty identification (only one study used CFS¹⁸).

10

Available information about the agreement of prestroke frailty measures with pre-mRS is also scant and their correlation appears to be, at the best, only moderate, with no clear dose-response patterns.^{3,4}

253 There are only four previous studies of CFS in older stroke patients admitted to SU, all of them using the older version of CFS scale.¹⁴ In a study of 433 IS patients aged \geq 75 years,¹⁸ CFS had no significant 254 correlation with pre-mRS; it was associated with 28-day mortality in the main cohort but unrelated to NIHSS 255 improvement after 24 hours in 63 patients undergoing reperfusion therapy. Another study²⁰ investigated 472 256 257 IS patients aged >65 years admitted to a stroke center able to provide only intravenous thrombolysis (patients with CFS 9 were excluded). CFS was weakly correlated with pre-mRS and predicted 28-day and 1-yr 258 259 mortality but did not predict either discharge setting in the main cohort and NIHSS improvement in 178 patients undergoing thrombolisis. AuROC comparisons of CFS and pre-mRS showed that CFS offered a 260 261 slight predictive advantage for mortality but not for discharge setting. Similarly to our results, all AuROC 262 estimates were below the 0.80 threshold. Noticeably, both the above mentioned studies tested that the 263 association of CFS with stroke outcomes was independent of age, stroke severity and comorbidities but did 264 not include pre-mRS as a confounder.

Two other studies using CFS focused on select subsets of IS older patients without prestroke disability who underwent mechanical thrombectomy. In 159 patients aged \geq 80 years, frailty was associated with poor functional outcome at 3 months (mRS >3) and 1-year mortality.²² In 198 patients aged \geq 70 years, there was low agreement between CFS and pre-mRS and frailty (here defined as CFS \geq 4) was associated with mRS at 90-day but not with length of hospital stay.²¹

In our stroke cohort, AuROC curves showed that CFS had a slightly better prognostic ability than pre-mRS 270 271 for some study outcomes but neither scale attained clinical meaningfulness for any. However, agreement 272 between the scales was low and multivariable analyses confirmed that CFS provided prognostic information 273 independent of prestroke disability measured with mRS. Additionally, the study showed that prestroke 274 frailty, independent of prestroke disability, was associated with several adverse outcomes of IS patients treated with reperfusion therapies. This agrees with results from a metanalysis of nine studies⁴⁰ (including all 275 276 the above mentioned four studies using CFS) that reported an association of frailty with poor functional 277 outcome and 1-year, but not 1-month, mortality in IS treated patients.

11

278 The U-shaped association we found between CFS and NIHSS improvement after reperfusion therapies is 279 particularly interesting. While it can be reasonable to expect that persons with mild-to-moderate frailty are 280 more susceptible to acute ischemic damage, the potential for neurologic improvement in patients with severe frailty may appear counterintuitive. However, several, not mutually exclusive explanations can be proposed. 281 First, in patients with severe frailty, pre-existent motor and cognitive impairment may interfere with a 282 reliable estimation of neurological impairment on hospital admission,³⁹ especially when using NIHSS that is 283 not intended to distinguish prestroke and acute deficits.²³ Second, patients with severe frailty might present 284 with greater neurological severity at IS onset independent of their actual structural ischemic damage because 285 of a lower brain reserve, concurrent confusional states, and comorbidities adding their confounding 286 effects.41-43 287

There is a strong evidence that patients with pre-stroke disability have a higher risk of unfavourable stroke outcomes and may derive less benefit from hyperacute reperfusion therapies.^{6,7}. However, mRS was not designed to measure prestroke disability; the wording of its grades in not suited to pre-stroke assessment; and the tool may misestimate a patient's ability to recover because it overvalues physical disability with respect to cognition and general health.^{6,9} At present, both European⁸ and US⁹ stroke guidelines on reperfusion therapies acknowledge that exclusion of patients on the sole ground of prestroke disability may not be justified.

The main strength of this study is the use of CFS version 2.0 for frailty identification in a large elderly cohort
taken from a a "real world" pool of consecutive, unselected stroke admissions.

This study has also several limitations. First, the retrospective design does not allow for establishing causal 297 298 links. Second, a single-center cohort limits generalizability of results. Third, pre-mRS scoring occurred at the 299 time of ED setting, while evaluating whether the patient was eligible for reperfusion therapy, and it was 300 performed by multiple observers. By contrast, CFS was scored post hoc, by two raters with similar 301 background who were spared the time pressure often occurring during hyperacute management of stroke. 302 Moreover, CFS scoring was based on information from the whole medical chart and some data may have not been available when pre-mRS was scored. A fourth limitation is that, since analyses were based on 303 observational data, we had to adjust for baseline differences and many important confounders may have been 304 left out. The relatively small size of the IS treated subset is another drawback that limits generalization of the 305

306	study findings. Moreover, as reperfusion treatment decisions for patients with prestroke disability were not
307	standardized, no conclusion can be drawn about the efficacy and safety of these procedures in our cohort.
308	However, as the use of reperfusion therapy in elderly persons with prestroke disability is still generally
309	low, ^{8,9} we believe that our data may be of interest and promote further investigations. A final limitation is the
310	lack of information on death causes and post-discharge functional outcome. Moreover, we used discharge
311	destination as a surrogate measure of post-stroke function and rehabilitation potential. Although we
312	ascertained that results for these outcomes did not change after exclusion of patients with pre-existing
313	disability already living in nursing homes prior to admision, the potential for misclassification must be
314	acknowledged.
315	In conclusion, our data suggest that CFS and pre-mRS are not a substitute for each other and CFS may help
316	to inform decisions in elderly patients admitted with acute stroke. CFS has several advantages over other
317	frailty tools: it encompasses a broad assessment of frailty based on clinical judgement, is quick, and does not
318	rely on direct measurement of specific items, specialized equipment, or extra staff. ⁴ Further work exploring
319	the relevant prognostic properties of CFS in acute stroke patients is necessary, particularly with respect to
320	treatment decisions.
321	
322	Study Funding
323	Basic Research Grant Ricerca Fondamentale Orientata from University of Bologna Grant #2021
324	
325	Disclosures
326	None
327	
328	Supplemental Material
329	Tables T1
330	Figures F1-F3
331	
332	
333	

13

334 References

- 1. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability,
- frailty, and comorbidity: implications for improved targeting and care. J. Gerontol. A Biol. Sci. Med.
 Sci. 2004;59:255–263.
- Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical
 practice and public health. *Lancet*. 2019;394:1365–1375.
- 340 3. Burton JK, Stewart J, Blair M, Oxley S, Wass A, Taylor-Rowan M, Quinn TJ. Prevalence and
- 341 implications of frailty in acute stroke: systematic review & meta-analysis. *Age Ageing*.
 342 2022;51:afac064.
- 343 4. Evans NR, Todd OM, Minhas JS, Fearon P, Harston GW, Mant J, Mead G, Hewitt J, Quinn TJ,
- Warburton EA. Frailty and cerebrovascular disease: Concepts and clinical implications for stroke
 medicine. *Int J Stroke*. 2022;17:251–259.
- van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the
 assessment of handicap in stroke patients. *Stroke*. 1988;19:604–607.
- Harrison JK, McArthur KS, Quinn TJ. Assessment scales in stroke: clinimetric and clinical
 considerations. *Clin Interv Aging*. 2013;8:201–211.
- Quinn TJ, Singh S, Lees KR, Bath PM, Myint PK, VISTA Collaborators. Validating and comparing
 stroke prognosis scales. *Neurology*. 2017;89:997–1002.
- 8. Berge E, Whiteley W, Audebert H, De Marchis GM, Fonseca AC, Padiglioni C, de la Ossa NP, Strbian
- D, Tsivgoulis G, Turc G. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis
 for acute ischaemic stroke. *Eur Stroke J.* 2021;6:1–62.
- 355 9. Ganesh A, Fraser JF, Gordon Perue GL, Amin-Hanjani S, Leslie-Mazwi TM, Greenberg SM, Couillard
- 356 P, Asdaghi N, Goyal M, American Heart Association Stroke Council. Endovascular treatment and
- 357 thrombolysis for acute ischemic stroke in patients with premorbid disability or dementia: a scientific
- 358 statement from the American Heart Association/American Stroke Association. *Stroke*. 2022;53:e204–
- 359 e217.

- 10. Gumbinger C, Ringleb P, Ippen F, Ungerer M, Reuter B, Bruder I, Daffertshofer M, Stock C, Stroke
- Working Group of Baden-Württemberg. Outcomes of patients with stroke treated with thrombolysis
 according to prestroke Rankin Scale scores. *Neurology*. 2019;93:e1834–e1843.
- 363 11. Ambagtsheer RC, Archibald MM, Lawless M, Kitson A, Beilby J. Feasibility and acceptability of
- 364 commonly used screening instruments to identify frailty among community-dwelling older people: a
 365 mixed methods study. *BMC Geriatrics*. 2020;20:152.
- 366 12. Dent E, Martin FC, Bergman H, Woo J, Romero-Ortuno R, Walston JD. Management of frailty:
 367 opportunities, challenges, and future directions. *Lancet*. 2019;394:1376–1386.
- 13. Buta BJ, Walston JD, Godino JG, Park M, Kalyani RR, Xue Q-L, Bandeen-Roche K, Varadhan R.
- Frailty assessment instruments: Systematic characterization of the uses and contexts of highly-cited
 instruments. *Ageing Res Rev.* 2016;26:53–61.
- Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global
 clinical measure of fitness and frailty in elderly people. *CMAJ*. 2005;173:489–495.
- 15. Daly RM, Iuliano S, Fyfe JJ, Scott D, Kirk B, Thompson MQ, Dent E, Fetterplace K, Wright ORL,
- Lynch GS, et al. Screening, diagnosis and management of sarcopenia and frailty in hospitalized older
- adults: recommendations from the Australian and New Zealand Society for Sarcopenia and Frailty
- Research (ANZSSFR) Expert Working Group. *J Nutr Health Aging*. 2022;26:637–651.
- 16. Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, Woo J,
- Aprahamian I, Sanford A, Lundy J, et al. Physical Frailty: ICFSR International Clinical Practice
 Guidelines for Identification and Management. *J Nutr Health Aging*. 2019;23:771–787.
- 38017.Fehlmann CA, Nickel CH, Cino E, Al-Najjar Z, Langlois N, Eagles D. Frailty assessment in
- emergency medicine using the Clinical Frailty Scale: a scoping review. *Intern Emerg Med.*
- **382** 2022;17:2407–2418.
- 18. Evans NR, Wall J, To B, Wallis SJ, Romero-Ortuno R, Warburton EA. Clinical frailty independently
 predicts early mortality after ischaemic stroke. *Age Ageing*. 2020;49:588–591.
- 19. Ng CC, Lim WC, Tan KM, Wong KY, Kanagarajah RR, Singh HSAK, Tan WG. Is pre-stroke frailty
 as determined by the Clinical Frailty Scale version 2.0 associated with stroke outcomes? *Singapore*
- 387 *Med J.* 2023;

- 15
- 20. Patel K, Shrier WEJ, Sengupta N, Hunt DCE, Hodgson LE. Frailty, assessed by the Rockwood Clinical
 Frailty Scale and 1-year outcomes following ischaemic stroke in a non-specialist UK stroke centre. *J Stroke Cerebrovasc Dis.* 2022;31:106451.

391 21. Tan BYQ, Ho JSY, Leow AS, Chia MLJ, Sia CH, Koh YY, Seetharaman SK, Yang C, Gopinathan A,

- Teoh HL, et al. Effect of frailty on outcomes of endovascular treatment for acute ischaemic stroke in
 older patients. *Age Ageing*. 2022;51:afac096.
- Tiainen M, Martinez-Majander N, Virtanen P, Räty S, Strbian D. Clinical frailty and outcome after
 mechanical thrombectomy for stroke in patients aged ≥ 80 years. *J Stroke Cerebrovasc Dis*.
 2022;31:106816.
- 23. Lyden P. Using the National Institutes of Health Stroke Scale: a cautionary tale. *Stroke*. 2017;48:513–
 519.
- Lindley RI, Wardlaw JM, Whiteley WN, Cohen G, Blackwell L, Murray GD, Sandercock PAG, Trial
 Steering Committee, Baigent C, Chadwick D, et al. Alteplase for Acute Ischemic Stroke: Outcomes by
 Clinically Important Subgroups in the Third International Stroke Trial. *Stroke*. 2015;46:746–756.
- 402 25. Fuentes B, Ntaios G, Putaala J, Thomas B, Turc G, Díez-Tejedor E. European Stroke Organisation
 403 (ESO) guidelines on glycaemia management in acute stroke. *European Stroke Journal*. 2018;3:5–21.
- 26. Saver JL, Chaisinanunkul N, Campbell BCV, Grotta JC, Hill MD, Khatri P, Landen J, Lansberg MG,
- 405 Venkatasubramanian C, Albers GW, et al. Standardized Nomenclature for Modified Rankin Scale
- Global Disability Outcomes: Consensus Recommendations From Stroke Therapy Academic Industry
 Roundtable XI. *Stroke*. 2021;52:3054–3062.
- 408 27. Rockwood K, Theou O. Using the Clinical Frailty Scale in Allocating Scarce Health Care Resources.
 409 *Can Geriatr J.* 2020;23:210–215.
- 410 28. Kabell Nissen S, Rueegg M, Carpenter CR, Kaeppeli T, Busch J-M, Fournaise A, Dreher-Hummel T,
- 411 Bingisser R, Brabrand M, Nickel CH. Prognosis for older people at presentation to emergency
- department based on frailty and aggregated vital signs. *J Am Geriatr Soc*. 2023;71:1250–1258.
- 413 29. Davies J, Whitlock J, Gutmanis I, Kane S-L. Inter-Rater Reliability of the Retrospectively Assigned
- 414 Clinical Frailty Scale Score in a Geriatric Outreach Population. *Can Geriatr J.* 2018;21:1–5.

- 16
- 415 30. Stille K, Temmel N, Hepp J, Herget-Rosenthal S. Validation of the Clinical Frailty Scale for
- 416 retrospective use in acute care. *Eur Geriatr Med.* 2020;11:1009–1015.
- 417 31. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic
- 418 comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40:373–383.
- 419 32. Corraini P, Szépligeti SK, Henderson VW, Ording AG, Horváth-Puhó E, Sørensen HT. Comorbidity
- 420 and the increased mortality after hospitalization for stroke: a population-based cohort study. *JTH*.
- 421 2018;16:242–252.
- 422 33. Fisher RJ, Byrne A, Chouliara N, Lewis S, Paley L, Hoffman A, Rudd A, Robinson T, Langhorne P,
- 423 Walker M. Effect of stroke early supported discharge on length of hospital stay: analysis from a

424 national stroke registry. *BMJ Open*. 2021;11:e043480.

- 34. Busl KM, Nogueira RG, Yoo AJ, Hirsch JA, Schwamm LH, Rost NS. Prestroke dementia is associated
 with poor outcomes after reperfusion therapy among elderly stroke patients. *J Stroke Cerebrovasc Dis*.
 2013;22:718–724.
- 428 35. Watson PF, Petrie A. Method agreement analysis: A review of correct methodology. *Theriogenology*.
 429 2010;73:1167–1179.
- 430 36. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated
 431 receiver operating characteristic curves: a nonparametric approach. *Biometrics*. 1988;44:837–845.
- 432 37. Hond AAH de, Steyerberg EW, Calster B van. Interpreting area under the receiver operating
 433 characteristic curve. *Lancet Digit Health*. 2022;4:e853–e855.
- 434 38. Huang YN, Yan FH, Wang XY, Chen XL, Chong HY, Su WL, Chen YR, Han L, Ma YX. Prevalence
 435 and Risk Factors of Frailty in Stroke Patients: A Meta-Analysis and Systematic Review. *J Nutr Health*436 *Aging*. 2023;27:96–102.
- 437 39. Smithard DG. Stroke in Frail Older People. *Geriatrics (Basel)*. 2017;2:24.
- 438 40. Bao Q, Huang X, Wu X, Chen S, Yang J, Zhang J, Li J, Yang M. Implications of frailty in acute
- 439 ischemic stroke receiving endovascular treatment: systematic review and meta-analysis. *Aging Clin*440 *Exp Res.* 2023;

	_
1	7
ь	1
_	•

- 441 41. Pinguet V, Duloquin G, Thibault T, Devilliers H, Comby P-O, Crespy V, Ricolfi F, Vergely C, Giroud
 442 M, Béjot Y. Pre-existing brain damage and association between severity and prior cognitive
- 443 impairment in ischemic stroke patients. *J Neuroradiol*. 2022;S0150-9861(22)00097–9.
- 444 42. Chen R-L, Balami JS, Esiri MM, Chen L-K, Buchan AM. Ischemic stroke in the elderly: an overview
 445 of evidence. *Nat Rev Neurol.* 2010;6:256–265.
- 446 43. Oldenbeuving AW, de Kort PLM, Jansen BPW, Roks G, Kappelle LJ. Delirium in Acute Stroke: A
- 447 Review. Int J Stroke. 2007;2:270–275.
- 448 44. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M,
- 449Demaerschalk BM, Hoh B, et al. Guidelines for the Early Management of Patients With Acute
- 450 Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic
- 451 Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American
- 452 Stroke Association. *Stroke*. 2019;50:e344–e418.
- 453 45. United Nations. World Population Prospects 2019: Data Booklet [Internet]. UN; 2019 [cited 2021 Jul
- 454 2]. Available from: https://www.un-ilibrary.org/content/books/9789210042475
- 455 46. Cruise C, Mfoafo M'Carthy N, Ganesh A, Lashewicz B. Imperfect Patients: Disparities in Treatment of
- 456 Stroke Patients with Premorbid Disability. *Can J Neurol Sci.* 2022;1–12.
- 457
- 458
- 459
- 460
- 461
- 462
- 463
- 464
- 465
- 466
- 167
- 467
- 468
- 469

Table 1. Population characteristics by Clinical Frailty Score (CFS)

		CFS		P-value
	1-3	4-6	7-8	-
	(n = 2385)	(n = 1203)	(n = 498)	
Age, yr	78 (72-83)	85 (80-89)	86 (82-91)	< 0.001
Female sex	1104 (46.3)	776 (64.5)	369 (74.1)	< 0.001
Prestroke disability	16 (0.7)	595 (49.5)	464 (93.2)	< 0.001
Living in institution before admission	7 (0.3)	70 (5.8)	145 (29.1)	< 0.001
Charlson Comorbidity Index				< 0.001
0	873 (36.6)	200 (16.6)	25 (5.0)	
1	752 (31.6)	356 (29.6)	124 (24.9)	
2-3	602 (25.2)	454 (37.7)	211 (42.4)	
<u>≥</u> 4	158 (6.6)	193 (16.1)	138 (27.7)	
Ischemic stroke	1966 (82.4)	982 (81.6)	426 (85.5)	0.147
Admission NIHSS score				< 0.001
0-5	1197 (50.2)	449 (37.3)	95 (19.1)	
6-15	662 (27.8)	389 (32.3)	155 (31.1)	
>15	526 (22.0)	365 (30.4)	248 (49.8)	
Poor functional outcome ^a	1409 (59.1)	921 (76.7)	327 (78.0)	< 0.001
Prolonged discharge ^b	1062 (53.7)	583 (60.4)	178 (48.0)	< 0.001
Unfavorable discharge	574 (24.1)	496 (41.2)	286 (57.4)	< 0.001
Poor rehabilitation potential ^c	168 (15.0)	259 (37.0)	159 (72.6)	< 0.001
30-day mortality	279 (11.7)	249 (20.7)	169 (33.9)	< 0.001
1-year mortality ^d	236 (11.4)	297 (31.9)	17 (47.6)	< 0.001

Data are reported as median (25-75th percentile) or number (percentage)

473	Abbreviations: NIHSS, National Institutes of Health Stroke Scale
474	
475	
476	
477	
478	
479	
480	

Table 2. Comparison of Clinical Frailty Scale (CFS) and preadmission modified Rankin scale (pre-mRS) for

485 prediction of the study outcomes.

	CFS	pre-mRS	P-value
Poor functional outcome	0.605 (0.588-0.621)*	0.581 (0.564-0.597)	< 0.001
Prolonged discharge	0.502 (0.483 - 0.520)	0.506 (0.488 - 0.524)	0.289
Unfavorable discharge	0.648 (0.630-0.666)	0.635 (0.618-0.652)	0.003
Poor rehabilitation potential	0.737 (0.713-0.761)	0.721 (0.697-0.745)	0.013
30-day mortality	0.639 (0.617-0.662)	0.637 (0.616-0.659)	0.710
1-year mortality	0.703 (0.681-0.725)	0.700 (0.678-0.723)	0.537

- 487 Data are areas under the curve (95% Confidence Intervals). P-values are for non-parametric comparison of
- 488 CFS and pre-mRS estimates.

20

510 Legends for figures

- **Figure 1.** The Clinical Frailty Scale version 2.0. Printed with permission from copyright holder.
- 512 Figure 2. Mosaic plot representing the study patients stratified by levels of Clinical Frailty Scale (CFS,
- borizontal axis) and prestroke modified Rankin Scale (pre-mRS, vertical axis). The width of the colums
- represents the number of observation for each CFS level. The height of each bar represent the number of
- 515 observations for individual pre-mRS levels within each CFS level.
- 516 Figure 3. Multivariable-adjusted associations of Clinical Frailty Scale (CFS) with the study outcomes from
- 517 multivariable-adjusted models. CFS was categorized as no frailty (score 1-3), mild to moderate frailty (score
- 4-6) and severe frailty (score 7-8). Panel A shows odds ratios (OR) and their 95% confidence intervals (95%
- 519 CI); panel B, hazard ratios (HR) and their 95% CI. All models included age, sex, Charlson Comorbidity
- 520 Index score, stroke subtype, admission NIHSS, and prestroke disability.
- 521 Figure 4. Multivariable-adjusted associations of frailty with the study outcomes in patients with ischemic
- 522 stroke treated with reperfusion therapies. Frailty was defined as Clinical Frailty Scale \geq 4. Panel A shows
- 523 odds ratios (OR) and their 95% confidence intervals (95% CI). Panel B shows the adjusted survival
- 524 probability curves for frail and non-frail patients. All models included age, sex, Charlson Comorbidity Index
- score, admission NIHSS, and prestroke disability.

CLINICAL FRAILTY SCALE

ţ	1	VERY Fit	People who are robust, active, energetic and motivated. They tend to exercise regularly and are among the fittest for their age.
t	2	FIT	People who have no active disease symptoms but are less fit than category 1. Often, they exercise or are very active occasionally , e.g., seasonally.
t	3	MANAGING Well	People whose medical problems are well controlled, even if occasionally symptomatic, but often are not regularly active beyond routine walking.
•	4	LIVING WITH VERY MILD FRAILTY	Previously "vulnerable," this category marks early transition from complete independence. While not dependent on others for daily help, often symptoms limit activities . A common complaint is being "slowed up" and/or being tired during the day.
	5	LIVING WITH MILD FRAILTY	People who often have more evident slowing, and need help with high order instrumental activities of daily living (finances, transportation, heavy housework). Typically, mild frailty progressively impairs shopping and walking outside alone, meal preparation medications and begins to restrict light housework.



SCORING FRAILTY IN PEOPLE WITH DEMENTIA

The degree of frailty generally corresponds to the degree of dementia. Common **symptoms in mild dementia** include forgetting the details of a recent event, though still remembering the event itself, repeating the same question/story and social withdrawal.



In moderate dementia, recent memory is very impaired, even though they seemingly can remember their past life events well. They can do personal care with prompting.

In severe dementia, they cannot do personal care without help.

In very severe dementia they are often bedfast. Many are virtually mute.

Clinical Frailty Scale ©2005–2020 Rockwood, Version 2.0 (EN). All rights reserved. For permission: www.geriatricmedicineresearch.ca Rockwood K et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489–495.



pre-mRS

Α



В





